Europe Biocatalysts Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Artificial intelligence is increasingly being integrated into enzyme discovery and optimisation across Europe. The EU-funded ELEGANCE project, which began in January 2026 with an EU contribution of approximately €4.47 million, combines machine learning, data science and experimental methods to design enzymes and optimise bioprocesses. Separately, researchers at Barcelona's Centre for Genomic Regulation published a 2026 review highlighting the growing maturity of generative AI for creating and improving industrial enzymes. These developments are reducing reliance on lengthy trial-and-error approaches and supporting faster identification of biocatalysts with targeted activity, selectivity and process characteristics for pharmaceutical and chemical manufacturing.

European biocatalysis is increasingly progressing from laboratory research toward commercially scalable manufacturing. The 2026 CBE JU programme allocated €170.7 million across 13 topics supporting bio-based innovation, including biotech-enabled biorefineries, alternative feedstocks and industrial-scale deployment. By September 2026, the programme had received 272 project proposals requesting €1.65 billion in funding, indicating substantial interest in scaling bio-based technologies. For biocatalysts, this creates opportunities beyond pharmaceutical synthesis, including chemicals, materials, food ingredients and agricultural applications. The emphasis on scale-up is also encouraging developers to address enzyme productivity, process economics, feedstock availability and integration into existing industrial bioprocessing infrastructure.

Improving enzyme stability is emerging as an important focus as European biocatalysis moves into demanding industrial environments. The EU-funded STABLE project, beginning in November 2026 at Technische Universität Berlin, is investigating structure-guided approaches to improve enzyme stability under conditions involving high substrate concentrations, elevated temperatures, extended reaction times and organic co-solvents. The project has received approximately €202,125 in EU funding and combines experimental stability profiling with computational modelling and molecular-dynamics approaches. Greater operational stability can help reduce enzyme replacement requirements and improve productivity, particularly where industrial reactions operate under conditions substantially different from the natural environments in which enzymes evolved.

European developers are placing greater emphasis on measuring both environmental and economic performance when selecting or engineering biocatalysts. A 2026 study published in ACS Sustainable Chemistry & Engineering highlights the use of economic and sustainability metrics at an early laboratory stage to benchmark processes and guide enzyme improvement. Metrics including productivity, yield, titre and specific yield can help determine whether an enzymatic route provides meaningful advantages before substantial investment in scale-up. This approach is particularly relevant as European biotechnology programmes increasingly prioritise sustainable manufacturing, resource efficiency and circular value chains. Consequently, enzyme performance is increasingly assessed alongside process economics and environmental outcomes rather than solely catalytic activity.

Pharmaceutical manufacturing continues to be an important application for advanced biocatalysts in Europe, particularly for producing complex active pharmaceutical ingredients with high selectivity. AstraZeneca's 2026 review describes biocatalysis as a strategic manufacturing capability, supported by enzyme identification, directed evolution, automated high-throughput experimentation and academic partnerships. The company is also moving toward end-to-end automated workflows and AI-enabled enzyme design. These capabilities can support selective transformations under milder conditions and potentially reduce waste and resource intensity compared with conventional chemical routes. The trend is strengthening demand for specialised enzyme libraries, engineered biocatalysts and process-development expertise within Europe's pharmaceutical manufacturing ecosystem.